105 related articles for article (PubMed ID: 11512406)
21. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
22. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference. Schirmerreschaft der Deutschen Gesellschaft for Nuklearmedizin].
Reske SN; Bares R; Büll U; Guhlmann A; Moser E; Wannenmacher MF
Nuklearmedizin; 1996 Apr; 35(2):42-52. PubMed ID: 8721575
[TBL] [Abstract][Full Text] [Related]
24. [Positron emission-computed tomography in diagnosis and staging of lung neoplasms. Personal experience].
Mezzetti M; Calati AM; Schubert L
Minerva Chir; 2002 Aug; 57(4):461-5. PubMed ID: 12145576
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
26. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
27. [Present status of PET images: clinical FDG PET in oncology].
Inoue T
Nihon Igaku Hoshasen Gakkai Zasshi; 1999 Nov; 59(13):737-44. PubMed ID: 10614103
[TBL] [Abstract][Full Text] [Related]
28. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
29. FDG PET in head and neck cancer.
Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF
AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography scanning: current and future applications.
Czernin J; Phelps ME
Annu Rev Med; 2002; 53():89-112. PubMed ID: 11818465
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic possibilities of positron emission tomography (PET): applications in oral and maxillofacial buccal oncology.
Carranza-Pelegrina D; Lomeña-Caballero F; Soler-Peter M; Berini-Aytés L; Gay-Escoda C
Med Oral Patol Oral Cir Bucal; 2005; 10(4):331-42. PubMed ID: 16056188
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography in gynecologic cancer.
Yen TC; Lai CH
Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
[TBL] [Abstract][Full Text] [Related]
33. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
34. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker.
Chang WC; Hung YC; Kao CH; Yen RF; Shen YY; Lin CC
Neoplasma; 2002; 49(5):329-33. PubMed ID: 12458332
[TBL] [Abstract][Full Text] [Related]
37. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Esophageal cancer].
Noboru O
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):265-9. PubMed ID: 12073632
[TBL] [Abstract][Full Text] [Related]
38. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma.
Freudenberg LS; Schueler AO; Beyer T; Antoch G; Kühl H; Bornfeld N; Bockisch A; Egelhof T
Surv Ophthalmol; 2004; 49(5):537-40. PubMed ID: 15325198
[TBL] [Abstract][Full Text] [Related]
39. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
40. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
